Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19.

Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Haaber J, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV.

Clin Cancer Res. 2019 Aug 22. pii: clincanres.1337.2019. doi: 10.1158/1078-0432.CCR-19-1337. [Epub ahead of print]

PMID:
31439577
2.

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.

Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV.

Nat Biotechnol. 2019 Sep;37(9):1049-1058. doi: 10.1038/s41587-019-0192-1. Epub 2019 Jul 22.

PMID:
31332324
3.

Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.

Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi BD, DeFilipp Z, Chen YB, Abramson J, Crombie J, Armand P, Nayak L, Panzini C, Riley LS, Gallagher K, Maus MV.

Blood. 2019 Sep 12;134(11):860-866. doi: 10.1182/blood.2019001694. Epub 2019 Jul 18.

PMID:
31320380
4.

Effects of intermittent T-cell cluster disaggregation on proliferative capacity and checkpoint marker expression.

Li M, Chin LY, Shukor S, Tamayo AG, Maus MV, Parekkadan B.

Autoimmunity. 2019 May;52(3):102-107. doi: 10.1080/08916934.2019.1630064. Epub 2019 Jun 25.

PMID:
31238751
5.

Gene editing for immune cell therapies.

Bailey SR, Maus MV.

Nat Biotechnol. 2019 Jun 3. doi: 10.1038/s41587-019-0137-8. [Epub ahead of print] Review.

PMID:
31160723
6.

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.

Baeuerle PA, Ding J, Patel E, Thorausch N, Horton H, Gierut J, Scarfo I, Choudhary R, Kiner O, Krishnamurthy J, Le B, Morath A, Baldeviano GC, Quinn J, Tavares P, Wei Q, Weiler S, Maus MV, Getts D, Schamel WW, Hofmeister R.

Nat Commun. 2019 May 7;10(1):2087. doi: 10.1038/s41467-019-10097-0.

7.

CAR-Based Approaches to Cutaneous T-Cell Lymphoma.

Scarfò I, Frigault MJ, Maus MV.

Front Oncol. 2019 Apr 16;9:259. doi: 10.3389/fonc.2019.00259. eCollection 2019. Review.

8.

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN.

N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.

PMID:
31042825
9.

Biomanufacturing for clinically advanced cell therapies.

Aijaz A, Li M, Smith D, Khong D, LeBlon C, Fenton OS, Olabisi RM, Libutti S, Tischfield J, Maus MV, Deans R, Barcia RN, Anderson DG, Ritz J, Preti R, Parekkadan B.

Nat Biomed Eng. 2018 Jun;2(6):362-376. doi: 10.1038/s41551-018-0246-6. Epub 2018 Jun 11. Review.

10.

Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer.

Leick M, Maus MV.

Cancer Discov. 2019 Apr;9(4):466-468. doi: 10.1158/2159-8290.CD-19-0073.

PMID:
30936218
11.

Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.

Boroughs AC, Larson RC, Choi BD, Bouffard AA, Riley LS, Schiferle E, Kulkarni AS, Cetrulo CL, Ting D, Blazar BR, Demehri S, Maus MV.

JCI Insight. 2019 Mar 14;5. pii: 126194. doi: 10.1172/jci.insight.126194.

12.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2019 Feb 21;4(4). pii: 127684. doi: 10.1172/jci.insight.127684. eCollection 2019 Feb 21. No abstract available.

13.

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.

Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J.

Blood. 2019 May 16;133(20):2212-2221. doi: 10.1182/blood-2018-12-893396. Epub 2019 Feb 26.

PMID:
30808634
14.

Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing.

Kleinstiver BP, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK.

Nat Biotechnol. 2019 Mar;37(3):276-282. doi: 10.1038/s41587-018-0011-0. Epub 2019 Feb 11.

15.

Engineering and Design of Chimeric Antigen Receptors.

Guedan S, Calderon H, Posey AD Jr, Maus MV.

Mol Ther Methods Clin Dev. 2018 Dec 31;12:145-156. doi: 10.1016/j.omtm.2018.12.009. eCollection 2019 Mar 15. Review.

16.

CAR-T cells beyond CD19, UnCAR-Ted territory.

Leick MB, Maus MV.

Am J Hematol. 2019 May;94(S1):S34-S41. doi: 10.1002/ajh.25398. Epub 2019 Jan 23. Review.

PMID:
30632631
17.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Review.

18.

Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.

Fishman JA, Hogan JI, Maus MV.

Clin Infect Dis. 2019 Aug 30;69(6):909-920. doi: 10.1093/cid/ciy1025.

PMID:
30520987
19.

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR.

J Immunother Cancer. 2018 Dec 4;6(1):137. doi: 10.1186/s40425-018-0460-5. Review.

20.

Closed loop bioreactor system for the ex vivo expansion of human T cells.

Li M, Chin LY, Shukor S, Tamayo A, Maus MV, Parekkadan B.

Cytotherapy. 2019 Jan;21(1):76-82. doi: 10.1016/j.jcyt.2018.10.009. Epub 2018 Nov 27.

PMID:
30497956
21.

Making CAR T Cells a Solid Option for Solid Tumors.

Schmidts A, Maus MV.

Front Immunol. 2018 Nov 8;9:2593. doi: 10.3389/fimmu.2018.02593. eCollection 2018. Review.

22.

Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.

Choi BD, Maus MV, June CH, Sampson JH.

Clin Cancer Res. 2019 Apr 1;25(7):2042-2048. doi: 10.1158/1078-0432.CCR-18-1625. Epub 2018 Nov 16. Review.

PMID:
30446589
23.

Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.

Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, Preffer FI, Weinstock DM, Maus MV.

Blood. 2018 Oct 4;132(14):1495-1506. doi: 10.1182/blood-2018-04-842708. Epub 2018 Aug 8. Erratum in: Blood. 2018 Dec 6;132(23):2527.

PMID:
30089630
24.

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery.

Tang L, Zheng Y, Melo MB, Mabardi L, Castaño AP, Xie YQ, Li N, Kudchodkar SB, Wong HC, Jeng EK, Maus MV, Irvine DJ.

Nat Biotechnol. 2018 Sep;36(8):707-716. doi: 10.1038/nbt.4181. Epub 2018 Jul 9.

25.

Toxicities associated with immunotherapies for hematologic malignancies.

Leick MB, Maus MV.

Best Pract Res Clin Haematol. 2018 Jun;31(2):158-165. doi: 10.1016/j.beha.2018.03.004. Epub 2018 Mar 28. Review.

PMID:
29909916
26.

Tumour tamed by transfer of one T cell.

Maus MV.

Nature. 2018 Jun;558(7709):193-195. doi: 10.1038/d41586-018-05251-5. No abstract available.

PMID:
29895908
27.

Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.

Choi BD, Curry WT, Carter BS, Maus MV.

Neurosurg Focus. 2018 Jun;44(6):E13. doi: 10.3171/2018.2.FOCUS17788.

PMID:
29852773
28.

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.

Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH.

Mol Ther. 2018 Jul 5;26(7):1855-1866. doi: 10.1016/j.ymthe.2018.05.003. Epub 2018 May 8.

29.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.

JCI Insight. 2018 Apr 19;3(8). pii: 120505. doi: 10.1172/jci.insight.120505. eCollection 2018 Apr 19. Erratum in: JCI Insight. 2019 Feb 21;4(4):.

30.

Engineering Chimeric Antigen Receptor T cells to Treat Glioblastoma.

Choi BD, O'Rourke DM, Maus MV.

J Target Ther Cancer. 2017 Aug;6(4):22-25.

31.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2017 Jul 19;9(399). pii: eaaa0984. doi: 10.1126/scitranslmed.aaa0984.

32.

Ibrutinib treatment improves T cell number and function in CLL patients.

Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC.

J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17.

33.

Immunotherapy for Brain Tumors.

Sampson JH, Maus MV, June CH.

J Clin Oncol. 2017 Jul 20;35(21):2450-2456. doi: 10.1200/JCO.2017.72.8089. Epub 2017 Jun 22. Review.

PMID:
28640704
34.

The Why, what, and How of the New FACT standards for immune effector cells.

Maus MV, Nikiforow S.

J Immunother Cancer. 2017 Apr 18;5:36. doi: 10.1186/s40425-017-0239-0. eCollection 2017.

35.

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.

Scarfò I, Maus MV.

J Immunother Cancer. 2017 Mar 21;5:28. doi: 10.1186/s40425-017-0230-9. eCollection 2017. Review.

36.

Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.

Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH.

J Immunother. 2017 Apr;40(3):104-107. doi: 10.1097/CJI.0000000000000160.

PMID:
28234665
37.

CARs in the Lead Against Multiple Myeloma.

Ormhøj M, Bedoya F, Frigault MJ, Maus MV.

Curr Hematol Malig Rep. 2017 Apr;12(2):119-125. doi: 10.1007/s11899-017-0373-2. Review.

38.

Immunology: T-cell tweaks to target tumours.

Maus MV.

Nature. 2017 Mar 2;543(7643):48-49. doi: 10.1038/nature21506. Epub 2017 Feb 22. No abstract available.

PMID:
28225762
39.

The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.

Bedoya F, Frigault MJ, Maus MV.

Mol Ther. 2017 Feb 1;25(2):314-320. doi: 10.1016/j.ymthe.2016.11.011. Review.

40.

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.

Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivière I, Merghoub T, Wolchok J, Renner C, Sadelain M.

Mol Ther Oncolytics. 2017 Jan 11;3:1-9. doi: 10.1038/mto.2016.23. eCollection 2016.

41.

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies.

Ruella M, Maus MV.

Comput Struct Biotechnol J. 2016 Sep 28;14:357-362. eCollection 2016. Review.

42.

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.

Maus MV, June CH.

Clin Cancer Res. 2016 Apr 15;22(8):1875-84. doi: 10.1158/1078-0432.CCR-15-1433. Review.

43.

CAR-T Cell Therapies From the Transfusion Medicine Perspective.

Fesnak A, Lin C, Siegel DL, Maus MV.

Transfus Med Rev. 2016 Jul;30(3):139-45. doi: 10.1016/j.tmrv.2016.03.001. Epub 2016 Mar 28. Review.

44.

Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.

Fraietta JA, Schwab RD, Maus MV.

Semin Oncol. 2016 Apr;43(2):291-9. doi: 10.1053/j.seminoncol.2016.02.006. Epub 2016 Feb 9. Review.

45.

Chimeric antigen receptor-modified T cells strike back.

Frigault MJ, Maus MV.

Int Immunol. 2016 Jul;28(7):355-63. doi: 10.1093/intimm/dxw018. Epub 2016 Mar 28. Review.

46.

Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.

Maus MV, Levine BL.

Oncologist. 2016 May;21(5):608-17. doi: 10.1634/theoncologist.2015-0421. Epub 2016 Mar 23. Review.

47.

Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.

Zhukovsky EA, Morse RJ, Maus MV.

Curr Opin Immunol. 2016 Jun;40:24-35. doi: 10.1016/j.coi.2016.02.006. Epub 2016 Mar 8. Review.

48.

Innate immune signaling in CLL.

Maus MV.

Blood. 2016 Jan 28;127(4):376-8. doi: 10.1182/blood-2015-11-679845.

49.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.

Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.

50.

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV.

Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.

Supplemental Content

Support Center